BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19713245)

  • 21. Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Kehl KL; Shen C; Litton JK; Arun B; Giordano SH
    Breast Cancer Res Treat; 2016 Jan; 155(1):165-73. PubMed ID: 26706041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
    Evans DG; Harkness E; Lalloo F; Howell A
    J Med Genet; 2014 Sep; 51(9):573-80. PubMed ID: 25053764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Schwartz MD; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill S; Jandorf L; Kelly SP; Heinzmann J; Zidell A; Khoury K
    Breast Cancer Res Treat; 2018 Aug; 170(3):517-524. PubMed ID: 29611029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
    Claus EB; Stowe M; Carter D
    Breast Cancer Res Treat; 2003 Mar; 78(1):7-15. PubMed ID: 12611452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
    Høberg-Vetti H; Eide GE; Siglen E; Listøl W; Haavind MT; Hoogerbrugge N; Bjorvatn C
    Acta Oncol; 2019 Feb; 58(2):175-181. PubMed ID: 30334464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
    Sardanelli F; Podo F; D'Agnolo G; Verdecchia A; Santaquilani M; Musumeci R; Trecate G; Manoukian S; Morassut S; de Giacomi C; Federico M; Cortesi L; Corcione S; Cirillo S; Marra V; ; Cilotti A; Di Maggio C; Fausto A; Preda L; Zuiani C; Contegiacomo A; Orlacchio A; Calabrese M; Bonomo L; Di Cesare E; Tonutti M; Panizza P; Del Maschio A
    Radiology; 2007 Mar; 242(3):698-715. PubMed ID: 17244718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations.
    Dite GS; Jenkins MA; Southey MC; Hocking JS; Giles GG; McCredie MR; Venter DJ; Hopper JL
    J Natl Cancer Inst; 2003 Mar; 95(6):448-57. PubMed ID: 12644538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.
    Jones T; McCarthy AM; Kim Y; Armstrong K
    Cancer Med; 2017 Jul; 6(7):1787-1798. PubMed ID: 28627138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the NCCN Clinical Criteria for Recommending
    Cropper C; Woodson A; Arun B; Barcenas C; Litton J; Noblin S; Liu D; Park M; Daniels M
    J Natl Compr Canc Netw; 2017 Jun; 15(6):797-803. PubMed ID: 28596260
    [No Abstract]   [Full Text] [Related]  

  • 35. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic counseling and testing for breast cancer risk in African Americans.
    Halbert CH
    LDI Issue Brief; 2006 Sep; 12(1):1-4. PubMed ID: 17302016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
    Lorenzo Bermejo J; Hemminki K
    Ann Oncol; 2004 Dec; 15(12):1834-41. PubMed ID: 15550590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.